
Stoke Biogen Present Dravet Therapy Data at AES 2025
Stoke and Biogen Share New Zorevunersen Data in Dravet Syndrome Stoke Therapeutics and Biogen have announced new long-term clinical data that continue to strengthen the evidence supporting zorevunersen as a potential first-in-class disease-modifying therapy for Dravet syndrome. The data were…












